Highlights Kancera AB

Equities

KAN

SE0015658570

Market Closed - Nasdaq Stockholm Other stock markets 08:59:30 10/05/2024 pm IST			5-day change	1st Jan Change
1.722 ^SEK	+17.14%		+13.14%	-62.11%

08/05	Kancera AB Announces Executive Changes	CI
03/05	Kancera AB Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kancera AB Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects	03/05	CI
Kancera AB Reports Earnings Results for the Full Year Ended December 31, 2023	23/02	CI
Kancera AB Signs A License Agreement with the University of Newcastle	23/02	CI
Kancera AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	23/02	CI
Kancera AB Presents the statistical Analysis of Top Line Data from the FRACTAL Study	06/02	CI
Kancera AB Reports Positive Top Line Results from the FRACTAL Study	20/12	CI
Kancera AB Provides Operational Update Regarding Fractalkine Block Blockers KAN567 and KAND145	17/11	CI
Kancera AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	17/11	CI
Kancera AB Receives Finnish Regulatory Agency Approval for Phase I Study of KAND145	23/23/23	CI
Kancera AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	18/23/18	CI
Kancera AB Announces Newly Published Research Publication Confirms the Potential for Kancera's Fractalkine Blocker KAND567 in Cardiovascular Disease	24/23/24	CI
Kancera AB Reports Dosing of First Patient in the KANDOVA Study	19/23/19	CI
Kancera AB Reports Earnings Results for the First Quarter Ended March 31, 2023	19/23/19	CI
Kancera AB Submits Application to Conduct First-In-Human Study of Kand145	24/23/24	CI
Kancera AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	21/23/21	CI
Kancera AB Reports Earnings Results for the Full Year Ended December 31, 2022	21/23/21	CI
Kancera AB Submits Regulatory Application to the Swedish Medical Products Agency to Conduct Clinical Studies of KAND567 in Ovarian Cancer	22/22/22	CI
Kancera AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	27/22/27	CI
Kancera AB Reports New Preclinical Results Supporting Potential for Its Ror1 Inhibitor in B-Cell Malignancies	27/22/27	CI
Kancera AB Reports Promising Preclinical Results from Studies of Its Fractalkine Axis Blocking Drug Candidates in B-Cell Lymphoma	20/22/20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Kancera AB

Equities

KAN

SE0015658570

Highlights

Filters